Impact of Dual Versus Single Antiplatelet Therapy on Major Cardiovascular Outcomes in Patients with Acute Coronary Syndrome in the Arabian Gulf <br> <br>.
To evaluate the association of dual versus single antiplatelet therapy with major adverse cardiovascular events (MACE) in Patients in the Arabian Gulf with acute coronary syndrome (ACS). Data were analyzed from 3559 patients with a diagnosis of ACS admitted to 29 hospitals in 4 Arabian Gulf countries (Bahrain, Kuwait, Oman and United Arab Emirates) from January 2012 to January 2013. Dual antiplatelet therapy (DAPT), consisting of aspirin and clopidogrel, was compared to aspirin alone. MACE included 12-months cumulative stroke/transient ischemic attack (TIA), myocardial infarction (MI), all-cause mortality and re-admissions for cardiac reasons, post discharge. Analyses were performed using multivariable logistic regression. A total of 74% (n = 2634) of the patients were on DAPT. At 12-months follow-up, patients on DAPT were significantly less likely to experience MACE events (adjusted OR (aOR), 0.73; 95% confidence interval (CI): 0.61 - 0.86; p < 0.001). Lower cardiovascular event rates were also consistent across the following MACE components; MI (aOR, 0.66; 95% CI: 0.49-0.88; p = 0.005), all-cause mortality (aOR, 0.69; 95% CI: 0.51-0.94; p = 0.018) and re-admissions for cardiac reasons (aOR, 0.79; 95% CI: 0.66-0.95; p = 0.011). Conversely, DAPT was adversely associated with increased risk of stroke/TIA (aOR, 1.68; 95% CI: 1.05-2.69; p = 0.030). DAPT, compared to aspirin therapy alone, was generally associated with better cardiovascular outcomes after an ACS event. However, DAPT was adversely associated with increased risk of stroke/TIA in ACS patients in the Arabian Gulf.